Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer
Objective To investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidation treatment after completing first-line treatment in patients with advanced ovarian cancer. Methods A retrospective chart review was conducted on patients treated at the Comprehensiv...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society of Obstetrics and Gynecology
2021-09-01
|
| Series: | Obstetrics & Gynecology Science |
| Subjects: | |
| Online Access: | http://www.ogscience.org/upload/pdf/ogs-21093.pdf |
| _version_ | 1818576432101588992 |
|---|---|
| author | Jieun Ko Hyeong In Ha Min Chul Choi Sang Geun Jung Hyun Park Won Duk Joo Seung Hun Song Chan Lee Joon Mo Lee |
| author_facet | Jieun Ko Hyeong In Ha Min Chul Choi Sang Geun Jung Hyun Park Won Duk Joo Seung Hun Song Chan Lee Joon Mo Lee |
| author_sort | Jieun Ko |
| collection | DOAJ |
| description | Objective To investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidation treatment after completing first-line treatment in patients with advanced ovarian cancer. Methods A retrospective chart review was conducted on patients treated at the Comprehensive Gynecologic Cancer Center between January 2014 and 2019. Based on the inclusion criteria, 24 eligible patients who received HIPEC (paclitaxel 175 mg/m2, for 90 minutes, at 42°C) (HIPEC group) as consolidation treatment after terminating the adjuvant chemotherapy were identified. Another 24 patients who met the inclusion criteria and did not receive HIPEC were matched, representing the non-HIPEC group. Disease-free survival (DFS) and overall survival (OS) were examined between the two groups. Results The median DFS was 28.7 and 24.2 months in the HIPEC and non-HIPEC groups, respectively (P=0.688). The 3-year DFS rates in the HIPEC and non-HPEC groups were 39.5% and 32.6%, respectively. However, the median OS was not determined. The 5-year OS rates in the HIPEC and non-HIPEC groups were 86.2% and 81.3%, respectively (P=0.850). One patient developed grade 3 neutropenia. Other patients experienced mild adverse events after HIPEC. Conclusion This study suggests that consolidation HIPEC could not support the survival benefit after completing the first-line treatment for patients with advanced ovarian cancer, although no severe specific safety issues were found. Therefore, randomized trials evaluating consolidation HIPEC for the management of ovarian cancer are warranted. |
| first_indexed | 2024-12-16T06:13:55Z |
| format | Article |
| id | doaj.art-b79715c35ef64346be8ca13b724374a3 |
| institution | Directory Open Access Journal |
| issn | 2287-8572 2287-8580 |
| language | English |
| last_indexed | 2024-12-16T06:13:55Z |
| publishDate | 2021-09-01 |
| publisher | Korean Society of Obstetrics and Gynecology |
| record_format | Article |
| series | Obstetrics & Gynecology Science |
| spelling | doaj.art-b79715c35ef64346be8ca13b724374a32022-12-21T22:41:20ZengKorean Society of Obstetrics and GynecologyObstetrics & Gynecology Science2287-85722287-85802021-09-0164543744310.5468/ogs.210938643Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancerJieun Ko0Hyeong In Ha1Min Chul Choi2Sang Geun Jung3Hyun Park4Won Duk Joo5Seung Hun Song6Chan Lee7Joon Mo Lee8 Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University, Seongnam, Korea Department of Obstetrics and Gynecology, Pusan National University Yangsan Hospital, Yangsan, Korea Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, KoreaObjective To investigate the therapeutic efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as consolidation treatment after completing first-line treatment in patients with advanced ovarian cancer. Methods A retrospective chart review was conducted on patients treated at the Comprehensive Gynecologic Cancer Center between January 2014 and 2019. Based on the inclusion criteria, 24 eligible patients who received HIPEC (paclitaxel 175 mg/m2, for 90 minutes, at 42°C) (HIPEC group) as consolidation treatment after terminating the adjuvant chemotherapy were identified. Another 24 patients who met the inclusion criteria and did not receive HIPEC were matched, representing the non-HIPEC group. Disease-free survival (DFS) and overall survival (OS) were examined between the two groups. Results The median DFS was 28.7 and 24.2 months in the HIPEC and non-HIPEC groups, respectively (P=0.688). The 3-year DFS rates in the HIPEC and non-HPEC groups were 39.5% and 32.6%, respectively. However, the median OS was not determined. The 5-year OS rates in the HIPEC and non-HIPEC groups were 86.2% and 81.3%, respectively (P=0.850). One patient developed grade 3 neutropenia. Other patients experienced mild adverse events after HIPEC. Conclusion This study suggests that consolidation HIPEC could not support the survival benefit after completing the first-line treatment for patients with advanced ovarian cancer, although no severe specific safety issues were found. Therefore, randomized trials evaluating consolidation HIPEC for the management of ovarian cancer are warranted.http://www.ogscience.org/upload/pdf/ogs-21093.pdfovarian neoplasmhyperthermic intraperitoneal chemotherapyintraperitonealchemotherapy |
| spellingShingle | Jieun Ko Hyeong In Ha Min Chul Choi Sang Geun Jung Hyun Park Won Duk Joo Seung Hun Song Chan Lee Joon Mo Lee Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer Obstetrics & Gynecology Science ovarian neoplasm hyperthermic intraperitoneal chemotherapy intraperitoneal chemotherapy |
| title | Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer |
| title_full | Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer |
| title_fullStr | Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer |
| title_full_unstemmed | Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer |
| title_short | Hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer |
| title_sort | hyperthermic intraperitoneal chemotherapy as consolidation treatment of advanced stage ovarian cancer |
| topic | ovarian neoplasm hyperthermic intraperitoneal chemotherapy intraperitoneal chemotherapy |
| url | http://www.ogscience.org/upload/pdf/ogs-21093.pdf |
| work_keys_str_mv | AT jieunko hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer AT hyeonginha hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer AT minchulchoi hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer AT sanggeunjung hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer AT hyunpark hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer AT wondukjoo hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer AT seunghunsong hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer AT chanlee hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer AT joonmolee hyperthermicintraperitonealchemotherapyasconsolidationtreatmentofadvancedstageovariancancer |